Antibe Therapeutics Current Valuation vs. Price To Earning
| ATBPF Stock | USD 0.22 0.00 0.00% |
For Antibe Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Antibe Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Antibe Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Antibe Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Antibe Therapeutics over time as well as its relative position and ranking within its peers.
Antibe |
Antibe Therapeutics Price To Earning vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Antibe Therapeutics's current stock value. Our valuation model uses many indicators to compare Antibe Therapeutics value to that of its competitors to determine the firm's financial worth. Antibe Therapeutics is rated third in current valuation category among its peers. It is rated second in price to earning category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Antibe Therapeutics' earnings, one of the primary drivers of an investment's value.Antibe Current Valuation vs. Competition
Antibe Therapeutics is rated third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 176.35 Million. Antibe Therapeutics has negative current valuation of (19.98 Million) contributing less than 1% to the industry.
Antibe Price To Earning vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Antibe Therapeutics |
| = | (19.98 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Antibe Therapeutics |
| = | (1.67) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Antibe Price To Earning Comparison
Antibe Therapeutics is currently under evaluation in price to earning category among its peers.
Antibe Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Antibe Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Antibe Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Antibe Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Antibe Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada. Antibe Therapeutics is traded on OTC Exchange in the United States.
Antibe Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Antibe Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Antibe Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Antibe Therapeutics' important profitability drivers and their relationship over time.
Use Antibe Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Antibe Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Antibe Therapeutics will appreciate offsetting losses from the drop in the long position's value.Antibe Therapeutics Pair Trading
Antibe Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Antibe Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Antibe Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Antibe Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Antibe Therapeutics to buy it.
The correlation of Antibe Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Antibe Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Antibe Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Antibe Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Antibe Therapeutics position
In addition to having Antibe Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sports Thematic Idea Now
Sports
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Antibe Pink Sheet
To fully project Antibe Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Antibe Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Antibe Therapeutics' income statement, its balance sheet, and the statement of cash flows.